Login to Your Account



PTC, CV In Potential $345M Cardiovascular Agreement

By Karen Pihl-Carey


Tuesday, June 13, 2006
Less than three months after signing its first major preclinical deal focused on infectious disease, PTC Therapeutics Inc. topped it with a new cardiovascular collaboration worth up to $345 million with CV Therapeutics Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription